Overview

A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis

Status:
Not yet recruiting

Trial end date:
2031-01-13

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the effectiveness and safety of ozanimod (RPC1063) in causing and maintaining clinical remission. Ozanimod will be administered orally to pediatric participants with moderate to severe active ulcerative colitis (UC) who have had an inadequate response to conventional therapy.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Bristol-Myers Squibb

Treatments:

Ozanimod